WallStSmart

CeriBell, Inc (CBLL)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 6713% more annual revenue ($6.07B vs $89.06M). EW leads profitability with a 17.7% profit margin vs -60.0%. EW earns a higher WallStSmart Score of 55/100 (C).

CBLL

Avoid

33

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.0

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CBLL.

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CBLL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
33.7%10/10

Revenue surging 33.7% year-over-year

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

Areas to Watch

CBLL4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$696.36M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-30.8%2/10

ROE of -30.8% — below average capital efficiency

Free Cash FlowQuality
$-10.95M2/10

Negative free cash flow — burning cash

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : CBLL

The strongest argument for CBLL centers on Revenue Growth. Revenue growth of 33.7% demonstrates continued momentum.

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bear Case : CBLL

The primary concerns for CBLL are EPS Growth, Market Cap, Return on Equity.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Key Dynamics to Monitor

CBLL profiles as a hypergrowth stock while EW is a mature play — different risk/reward profiles.

CBLL is growing revenue faster at 33.7% — sustainability is the question.

EW generates stronger free cash flow (354M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EW scores higher overall (55/100 vs 33/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CeriBell, Inc

HEALTHCARE · MEDICAL DEVICES · USA

CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in Sunnyvale, California.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?